This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Omnicare CEO Discusses Q4 2011 Results - Earnings Call Transcript

For simplicity sake and the focus on what we believe are the best indicators of our operating performance, we will discuss results from continuing operations and we’ll also exclude special items for all periods in our discussion today.

A reconciliation of this non-GAAP information has been attached to our earnings release and is also available on our newly redesigned website. Also on our website, you will find fourth quarter supplemental slides and the historical data behind our cash based EPS reporting methodology, which we will follow when we report our first quarter results.

Before turning the call over to John, I would like to remind analysts to limit themselves to one question and one follow-up during our question-and-answer session so others may ask their questions.

With that, it is my pleasure to turn the call over to John Figueroa.

John Figueroa

Thanks Patrick. Good morning everyone, and thank you for joining us. Before we provide our perspective on our strong fourth quarter results and 2012 outlook, I’d like to briefly discuss our decision to allow a tender offer to acquire PharMerica to expire. Following our remarks, we’ll be happy to answer your questions.

In respect to PharMerica, while we strongly disagree with the FDCs decision to seek to block the proposed transaction, I believe we made the right decision to avoid investing significant time and money in a lawsuit to allow our tender offer to purchase all outstanding shares of PharMerica to expire.

While we believe the FDC failed to recognize the tremendous value, the combined entity would have offered the healthcare supply train, Omnicare’s business is performing well, and I believe we are well positioned to effect such change organically.

With such unique developments as OmniviewDr, which offers the first electronic prescribing solution for controlled substances in institutional settings, and Omnicare’s Proprietary Automation, which succeeds Six Sigma quality and prescription dispensing, I believe Omnicare’s actively revolutionized in quality and innovation in our industry.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs